Important Notice regarding Dextenza and Klarity-C

Posted in Latest News on October 15, 2019.

During the September 27, 2019 Board of Optometry meeting, the Board approved Dextenza (dexamethasone ophthalmic insert) 0.4 mg and approved Klarity-C (cyclosporine) 0.1% for addition to Rule 64B13-18.002, Florida Administrative Code – Formulary of Topical Pharmaceutical Agents.

Important Note: At this time, Dextenza and Klarity-C cannot be prescribed by Certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on the board website and both may be prescribed by Certified Optometrists at that time.



More Latest News

Board Website Re-Design Survey
November 15, 2023

MQA is planning to revamp the board websites. Please take the survey to give us your recommendations by clicking the survey icon below. Survey closing Friday, 2/2/2024 at 4:30 PM ET Continue reading


Announcing the FY 2022-23 Annual Report and Long-Range Plan
November 1, 2023

An annual publication showcasing trends and information about Florida’s health care regulatory landscape. Continue reading




Survey Button